Strategies of antiretroviral therapy in adults

Urologic Clinics of North America

Volumn 26, Issue 4, 1999, Pages 809-820

  Itani, S ^a   Bartlett, J A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

BLOOD DISEASE; DISEASE MARKER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW;

EID: 0032704120     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70221-4     Document Type: Article

References (53)

1. B. Autran G. Carcelain T.S. Li Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease Science 277 1997 112 116
2. D.R. Blum M.K. Wallack The surgeon's database for AIDS: A collective review J Am Coll Surg 184 1997 403 412
3. Cameron W, Heath-Chiozzi M, Kravcik S, et al: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract LB6a]. Presented at the Third National Conference on Retroviruses and Opportunistic Infections, Washington, DC, February 7, 1996
4. Y. Cao P. Krogstad B. Korber Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant Nat Med 3 1997 549 552
5. C. Carpenter M. Fischl S. Hammer Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society–USA Panel JAMA 227 1997 1962 1969
6. S. Carr K. Samaras D.J. Chosholm Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidacemia, and insulin resistance Lancet 351 9119 1998 1881 1883
7. W. Cavert D. Notermans K. Staskus Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection Science 276 1997 960 964
8. Chiasson M, Berenson L, Li, W, et al: Declining AIDS mortality in New York City [abstract 376]. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997
9. T. Chun L. Carruth D. Finzi Quantification of latent tissue resorvoirs and total body viral load in HIV-1 infection Nature 387 1997 183 187
10. S.J. Clark M.S. Saag W.D. Decker High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection N Engl J Med 324 1991 954 960
11. M. Connors J. Kovacs S. Krevat HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies Nat Med 5 1997 533 540
12. E.S. Daar T. Mougdil R.D. Meyer Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection N Engl J Med 324 1991 961 964
13. S.A. Danner A. Carr J.M. Leonard A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease N Engl J Med 333 1995 1528 1533
14. Delta Coordinating Committee Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals Lancet 348 1996 283 291
15. A. Erice D. Mayers D. Strike Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1 N Engl J Med 328 1993 1163 1165
16. J.J. Eron S.L. Benoit J. Jemsek The safety and efficacy of lamivudine, zidovudine or both in the treatment of HIV-positive patients with CD4+ cell counts of 200–500 cells per cubic millimeter N Engl J Med 333 1995 1662 1669
17. Granneman G, Hsu A, Sun E, et al: Pharmacokinetics/pharmacodynamics of ritonavir-saquinavir combination therapy [abstract 609] Presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, February 1997
18. R.M. Gulick J. Mellors D. Havlir Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection on prior antiretroviral therapy N Engl J Med 337 1997 734 739
19. S. Hammer D. Katzenstein M. Hughes A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter N Engl J Med 335 1996 1081 1090
20. S. Hammer K. Squires M. Hughes A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less N Engl J Med 337 1997 725 733
21. C. Hicks S. Myers J. Giner Resolution of intractable molluscum contagiosum in a human immunodeficiency virus–infected patient after institution of antiretroviral therapy with ritonavir Clin Infect Dis 24 1997 1023 1025
22. D.D. Ho A.U. Neumann A.S. Perelson Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 1995 123 126
23. M.D. Hughes V.A. Johnson M. Hirsch Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response Ann Intern Med 126 1997 929 938
24. D. Katzenstein S. Hammer M. Hughes The relation of virologic and clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter N Engl J Med 335 1996 1091 1098
25. Kempf D, Rode R, Xu Y, et al: The durability of response to protease inhibitor therapy is predicted by viral load [abstract 62]. Presented at the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June 1997
26. J.B. Kopp K.D. Miller J.M. Mican Crystalluria and urinary tract abnormalities associated with indinavir Ann Intern Med 127 1997 119 125
27. Kravcik S, Sahai J, Karr B, et al: Nelfinavir mesylate (NFV) increases Saquinavir - soft gel capsule (SQV - SGC) exposure in HIV + patients [abstract 371]. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997
28. Markowitz M, Cao Y, Hurley A, et al: Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1 [abstract TH.B.933]. Presented at the XIth International Conference on AIDS, Vancouver, Canada, 1996
29. M. Markowitz M. Saag W.G. Powderly A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med 333 1995 1534 1539
30. J.W. Mellors L.A. Kingsley C.R. Rinaldo Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med 122 1995 573 579
31. J.W. Mellors A. Munoz J. Giorgi Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection Ann Intern Med 126 1997 946 954
32. J.W. Mellors C.R. Rinaldo P. Gupta Prognosis of HIV-1 infection predicted by the quantity of virus in plasma Science 272 1996 1167 1170
33. D.P. Merrill M. Moonis C. Ting-Chao Lamivudine or stavudine in two and three drug combinations against human immunodeficiency virus type 1 or replication in vitro J Infect Dis 173 1996 355 364
34. A. Molla M. Kornevera Q. Gao Ordered accumulation of mutations in HIV-protease confers resistance to ritonavir Nat Med 2 1996 760 766
35. L. Musey J. Hughes T. Shacker Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection N Engl J Med 337 1997 1267 1274
36. W.A. O'Brien P.M. Hartigan E.S. Daar for the VA Cooperative Study Group on AIDS Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure Ann Intern Med 126 1997 939 945
37. W.A. O'Brien P.M. Hartigan D. Martin Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS N Engl J Med 334 1996 426 431
38. W.A. O'Brien K. Grovit-Ferbas A. Namazi Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza immunization Blood 86 1995 1082 1089
39. G. Pantaleo C. Graziosi L. Butini Lymphoid organs function as major reservoirs for human immunodeficiency virus Proc Natl Acad Sci USA 88 1991 9838 9842
40. G. Pantaleo C. Graziosi J.F. Demarest HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease Nature 362 1993 355 358
41. W.B. Paxton R.W. Coombs M.J. McElrath Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus–infected subjects with 400 CD4 lymphocytes: Implications for applying measurements to individual patients J Infect Dis 195 1997 247 254
42. A.N. Phillips J. Eron J.A. Bartlett HIV-1 RNA levels and the development of clinical disease AIDS 10 1996 859 865
43. S.D. Pinkerton D.R. Holtgrave H.J. Pinkerton Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV Arch Intern Med 157 1997 1972 1980
44. Pollard R, Peterson D, Hardy D, et al: Stavudine (D4T) and didanosine (ddI) combination therapy in HIV-infected subjects: Antiviral effect and safety in an ongoing pilot randomized double-blinded trial [abstract ThB.293]. Presented at the XIth International Conference on AIDS, Vancouver, BC, 1996
45. M.T.L. Roos J. Lange R. de Goede Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection J Infect Dis 165 1992 427 432
46. M. Saag M. Holodniy D.R. Kuritzkes HIV viral load markers in clinical practice Nat Med 2 1996 625 629
47. Schapiro J, Winters M, Vierra M, et al: Causes of long-term efficacy and/or drug failure in protease (PR) inhibitor monotherapy [abstract Mo.B.41]. Presented at the XIth International Conference on AIDS, Vancouver, BC, 1996
48. T. Shacker A.C. Collier J. Hughes Clinical and epidemiologic features of primary HIV infection Ann Intern Med 1996 257 264
49. A. Spira P. Marx B. Patterson Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques J Exp Med 183 1996 215 225
50. Update Trends in AIDS incidence, deaths, and prevalence—United States, 1996 MMWR 46 1997 165 173
51. Update Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV JAMA 276 1996 90 92
52. P.L. Vernazza B.L. Gilliam J. Dyer Quantification of HIV in semen: Correlation with antiviral treatment and immune status AIDS 11 1997 987 993
53. X. Wei S.K. Ghosh M.E. Taylor Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 1995 117 122